{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:54:39Z","timestamp":1790117679844,"version":"4.0.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In December 2022, Pluvicto\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (lutetium(177Lu)-vipivotide tetraxetan) received European Medicine Agency approval based on the Phase III VISION study as the first radioligand therapy (RLT) directed against prostate-specific membrane antigen (PSMA) and using Lutetium-177 (\n                      <jats:sup>177<\/jats:sup>\n                      Lu) for the treatment of metastatic prostate cancer. The objective of this study was to explore current barriers to the provision of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA RLT by drawing on the experiences of providers and to outline potential solutions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighteen physicians involved in the care of metastatic prostate cancer in the outpatient and inpatient settings from different regions of Germany participated in this semi-structured, qualitative expert interview study. Qualitative content analysis with inductive category formation was used to analyze the data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four major thematic categories were identified regarding barriers to care: (a) research-practice gap, (b) challenges to interprofessional collaboration, (c) resource constraints, and (d) unwarranted variation in care. Expert suggestions for resolving these barriers were grouped into the corresponding major thematic categories: (a) knowledge management, (b) integration of care, (c) capacity planning, and (d) facilitation of access.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The delivery of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA RLT faces several obstacles, including challenges in collaboration, resource allocation, and reimbursement solutions. Minimizing bureaucratic hurdles in forming healthcare teams is essential to enhance interprofessional coordination. Resources should be evaluated and distributed based on local needs, and expanding reimbursement options for prior diagnostics is critical to ensure early treatment access. Overcoming these barriers and adapting health systems to novel therapies like RLT are essential steps toward improving cancer care and patient outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-025-13540-9","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T07:36:17Z","timestamp":1759390577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Barriers and solutions in cross-sector care for metastatic prostate cancer patients in Germany: a qualitative study on radioligand therapy"],"prefix":"10.1186","volume":"25","author":[{"given":"Carolin","family":"Schenzle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"issue":"1","key":"13540_CR1","first-page":"28","volume":"27","author":"R Baum","year":"2022","unstructured":"Baum R. Radiomolecular precision oncology: a comprehensive treatment approach with high potential. Eur Pharm Rev. 2022, Feb;27(1):28\u201331.","journal-title":"Eur Pharm Rev"},{"key":"13540_CR2","unstructured":"Lenzen-Schulte M. Radioligandentherapie: Die Ultima Ratio beim Prostatakrebs. Deutsches \u00c4rzteblatt [Internet]. 2017, Nov, 3;44(114). Available from: https:\/\/www.aerzteblatt.de\/archiv\/194228\/Radioligandentherapie-Die-Ultima-Ratio-beim-Prostatakrebs. [cited 2023 Apr 12]."},{"key":"13540_CR3","unstructured":"Pluvicto EMA. EPAR - Product information [Internet]. 2023 Feb. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pluvicto-epar-product-information_en.pdf. [cited 2023 Apr 10]."},{"issue":"12","key":"13540_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021, Sep, 16;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"key":"13540_CR5","unstructured":"D. Metastasierter Prostatakrebs: Neues Medikament (Pluvicto\u00ae) in Europa zugelassen - [Internet]. 2022. Available from: https:\/\/www.krebsinformationsdienst.de\/aktuelles\/2022\/news059-metastasierter-prostatakrebs-zulassung-pluvicto-lutetium-177-psma-617-europa.php. [cited 2023 Apr 10]."},{"key":"13540_CR6","unstructured":"Pluvicto EMA. EPAR - Medicine overview [Internet]. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/pluvicto-epar-medicine-overview_en.pdf. [cited 2023 May 24]."},{"issue":"10","key":"13540_CR7","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","volume":"15","author":"U Hennrich","year":"2022","unstructured":"Hennrich U, Eder M. [177Lu]Lu-PSMA-617(PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022, Oct, 20;15(10):1292.","journal-title":"Pharmaceuticals (basel)"},{"key":"13540_CR8","doi-asserted-by":"publisher","first-page":"175883592311576","DOI":"10.1177\/17588359231157632","volume":"15","author":"A Jang","year":"2023","unstructured":"Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023, Mar, 4;15:17588359231157632.","journal-title":"Ther Adv Med Oncol"},{"key":"13540_CR9","unstructured":"Novartis. Novartis. Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer. 2022. Available from: https:\/\/www.novartis.com\/news\/media-releases\/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer. [cited 2023 Apr 9]."},{"key":"13540_CR10","unstructured":"Novartis Pharmaceuticals. PSMAfore: a phase III, open-label, multi-center, randomized study comparing 177Lu-PSMA-617 vs. A change of androgen receptor-directed therapy in the treatment of taxane Na\u00efve men with progressive metastatic castrate resistant prostate cancer [Internet]. clinicaltrials.govclinicaltrials.gov; Report No.: NCT04689828. 2023, Jul. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04689828. [cited 2023 Jul 19]."},{"key":"13540_CR11","unstructured":"Novartis Pharmaceuticals. An open-label, randomized, phase III study comparing 177Lu-PSMA-617 in combination with standard of care, versus standard of care alone, in adult male patients with metastatic hormone sensitive prostate cancer (mHSPC). [Internet]. clinicaltrials.gov; 2023, Jul. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04720157. [cited 2023 Jul 19]. Report No.: NCT04720157."},{"key":"13540_CR12","unstructured":"The Health Policy Partnership. Health system readiness for radioligand therapy in the US: situation analysis report. 2021, Nov.30. London."},{"issue":"6","key":"13540_CR13","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00259-020-04745-7","volume":"47","author":"C Merkel","year":"2020","unstructured":"Merkel C, Whicher CH, Bomanji J, Herrmann K, \u0106wik\u0142a J, Jervis N, et al. Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe. Eur J Nucl Med Mol Imaging. 2020;47(6):1335\u201339.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"13540_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1055\/a-1929-6599","volume":"148","author":"K Berger-Th\u00fcrmel","year":"2023","unstructured":"Berger-Th\u00fcrmel K, Westphalen CB, von B-BM. Patient access - Zugang zu Innovationen in der Onkologie. Dtsch Med Wochenschr. 2023, Mar;148(6):306\u201312.","journal-title":"Dtsch Med WochenschR"},{"key":"13540_CR15","unstructured":"The Health Policy Partnership. Radioligand therapy: releasing the potential of targeted cancer care [Internet]. 2020 Jan. Available from: https:\/\/www.healthpolicypartnership.com\/app\/uploads\/Radioligand-therapy-realising-the-potential-of-targeted-cancer-care.pdf p. 21."},{"issue":"8","key":"13540_CR16","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00259-020-05102-4","volume":"48","author":"C Hehakaya","year":"2021","unstructured":"Hehakaya C, Moors EHM, Verkooijen HM, Grobbee DE, Verburg FA, Lam MGEH. 177Lu-PSMA for advanced prostate cancer: are we ready to play big? Eur J Nucl Med Mol Imaging. 2021, Jul, 1;48(8):2325\u201328.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"13540_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1055\/a-1351-0030","volume":"60","author":"C Zippel","year":"2021","unstructured":"Zippel C, Giesel FL, Kratochwil C, Eiber M, Rahbar K, Albers P, et al. PSMA-Radioligandentherapie k\u00f6nnte Nuklearmedizin vor infrastrukturelle Herausforderungen stellen: Ergebnisse einer Basiskalkulation zur Kapazit\u00e4tsplanung nuklearmedizinischer Betten im deutschen Krankenhaussektor. Nuklearmedizin. 2021, Jun;60(3):216\u201323.","journal-title":"Nuklearmedizin"},{"key":"13540_CR18","doi-asserted-by":"crossref","unstructured":"Kaiser R. Qualitative Experteninterviews: Konzeptionelle Grundlagen und praktische Durchf\u00fchrung [Internet]. Wiesbaden: Springer Fachmedien; 2014. Available from: https:\/\/link.springer.com\/10.1007\/978-3-658-02479-6. [cited 2023 May 10].","DOI":"10.1007\/978-3-658-02479-6"},{"key":"13540_CR19","unstructured":"BMC. Intersektorale Versorgung ohne Therapiebr\u00fcche Forderungen der Arbeitsgruppe Intersektorale Versorgung im BMC [Internet]. 2019 Apr. Available from: https:\/\/www.bmcev.de\/wp-content\/uploads\/Forderungskatalog_AG-Intersektorale-Versorgung-1.pdf. [cited 2023 May 1] p. 4."},{"issue":"24","key":"13540_CR20","first-page":"1162","volume":"114","author":"H Korzilius","year":"2017","unstructured":"Korzilius H. Sektor\u00fcbergreifende Versorgung: Ambulante Angebote ausbauen. Deutsches \u00c4rzteblatt. 2017, Jun, 16;114(24):1162\u201363.","journal-title":"Deutsches \u00c4rzteblatt"},{"issue":"1","key":"13540_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11135-005-1098-1","volume":"41","author":"AJ Onwuegbuzie","year":"2007","unstructured":"Onwuegbuzie AJ, Leech NL. A call for qualitative power analyses. Qual Quant. 2007, Feb, 1;41(1):105\u201321.","journal-title":"Qual Quant"},{"key":"13540_CR22","first-page":"152 p","volume-title":"Qualitative Inhaltsanalyse: Grundlagen und Techniken. 12., \u00fcberarbeitete Auflage","author":"P Mayring","year":"2015","unstructured":"Mayring P. Qualitative Inhaltsanalyse: Grundlagen und Techniken. 12., \u00fcberarbeitete Auflage. Weinheim Basel: Beltz; 2015. p. 152."},{"key":"13540_CR23","doi-asserted-by":"crossref","DOI":"10.4135\/9781036231798","volume-title":"Qualitative content analysis: a step-by-step guide","author":"P Mayring","year":"2022","unstructured":"Mayring P. Qualitative content analysis: a step-by-step guide. Thousand Oaks: SAGE Publications; 2022."},{"key":"13540_CR24","unstructured":"Leitlinienprogramm Onkologie: Prostatakarzinom [Internet]. Available from: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakarzinom. [cited 2025 Aug 13]."},{"key":"13540_CR25","unstructured":"DKG. S3-Leitlinie Prostatakarzinom, Langversion 6.2.2021. Oct."},{"key":"13540_CR26","unstructured":"EAU. Uroweb - European Association of Urology. EAU guidelines on prostate cancer - Uroweb. Available from: 2023. https:\/\/uroweb.org\/guidelines\/prostate-cancer. [cited 2023 Dec 20]."},{"key":"13540_CR27","unstructured":"Nccn NCCN. NCCN guidelines prostate cancer. 2023. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail. [cited 2023 Dec 20]."},{"key":"13540_CR28","volume-title":"F\u00fcr eine gute und gerechte Gesundheitsversorgung","author":"MD","year":"2022","unstructured":"MD. F\u00fcr eine gute und gerechte Gesundheitsversorgung. 2022 Apr."},{"key":"13540_CR29","unstructured":"KBV. Verg\u00fctung der PSMA-PET zur Indikationsstellung einer Therapie mit Pluvicto\u00ae geregelt [Internet]. Kassen\u00e4rztliche Bundesvereinigung (KBV). 2023. Available from: https:\/\/www.kbv.de\/html\/1150_65673.php. [cited 2023 Dec 5]."},{"key":"13540_CR30","unstructured":"GBA. Richtlinie des Gemeinsamen Bundesausschusses \u00fcber die ambulante spezialfach\u00e4rztliche Versorgung ALT [Internet]. 2023 Mar. Available from: https:\/\/www.g-ba.de\/downloads\/62-492-3245\/ASV-RL_2023-03-16_iK_2023-09-19.pdf. [cited 2023 Dec 5]."},{"key":"13540_CR31","unstructured":"DKG. S3-Leitlinie Prostatakarzinom. Langversion. 2024, May;7"},{"key":"13540_CR32","volume-title":"Anspruch und Realit\u00e4t von Budgetverhandlungen zur Umsetzung medizintechnischer Innovationen Gutachten des Deutschen Krankenhausinstituts (DKI) im Auftrag des Bundesverbandes Medizintechnologie (BVMed)","author":"K Blum","year":"2009","unstructured":"Blum K, Offermanns M. Anspruch und Realit\u00e4t von Budgetverhandlungen zur Umsetzung medizintechnischer Innovationen Gutachten des Deutschen Krankenhausinstituts (DKI) im Auftrag des Bundesverbandes Medizintechnologie (BVMed). D\u00fcsseldorf; 2009 Nov."},{"issue":"10","key":"13540_CR33","first-page":"607","volume":"33","author":"RI Field","year":"2008","unstructured":"Field RI. Why is health care regulation so complex? P T. 2008, Oct;33(10):607\u201308.","journal-title":"P T"},{"issue":"4","key":"13540_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.15171\/ijhpm.2017.95","volume":"7","author":"L Ansmann","year":"2017","unstructured":"Ansmann L, Pfaff H. Providers and patients caught between standardization and individualization: individualized standardization as a solution. Int J Health Policy Manag. 2017, Aug, 12;7(4):349\u201352.","journal-title":"Int J Health Policy Manag"},{"key":"13540_CR35","unstructured":"Baes S, Horlai M, Leys M, Dhaene S. Physicians\u2019 attitudes and perspectives regarding the uptake of psychosocial aspects and\/or patient preferences during multidisciplinary team meetings in oncology-2020. 2020 [Internet]. Available from: https:\/\/journals.sagepub.com\/doi\/abs\/10.1177\/2053434520959678. [cited 2023 Aug 20]."},{"key":"13540_CR36","unstructured":"Gruber C. Realisierung der lokoregion\u00e4ren Tumorkonferenzempfehlungen im Versorgungsalltag von Mammakarzinom-Patientinnen des Brustzentrums der Charit\u00e9 Berlin [Internet]. 2012 Feb. Available from: https:\/\/refubium.fu-berlin.de\/bitstream\/handle\/fub188\/12848\/DissOnline-Pdf.pdf;jsessionid=9EC159928A1A94F2D92A9F1524D5CB45?sequence=1. [cited 2023 Aug 20]."},{"issue":"6","key":"13540_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1159\/000446311","volume":"39","author":"K Hermes-Moll","year":"2016","unstructured":"Hermes-Moll K, Dengler R, Riese C, Baumann W. Tumor boards from the perspective of ambulant oncological care. Oncol Res Treat. 2016;39(6):377\u201383.","journal-title":"Oncol Res Treat"},{"key":"13540_CR38","unstructured":"WINHO. Multidisziplin\u00e4re Tumorkonferenzen: Strukturen, Prozesse und Anforderungen aus Sicht der \u00c4rztinnen und \u00c4rzte [Internet]. Wissenschaftliches Institut der Niedergelassenen H\u00e4matologen und Onkologen - WINHO - GmbH. 2023 Dec. Available from: https:\/\/www.zi.de\/fileadmin\/Downloads\/Service\/Forschungsfoerderung\/2020\/Heidt_WINHO.pdf. [cited 2023 Aug 20]."},{"issue":"9","key":"13540_CR39","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1245\/s10434-017-5833-3","volume":"24","author":"YL Basta","year":"2017","unstructured":"Basta YL, Bolle S, Fockens P, Tytgat KMAJ. The value of multidisciplinary team meetings for patients with gastrointestinal malignancies: a systematic review. Ann Surg Oncol. 2017, Sep;24(9):2669\u201378.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"13540_CR40","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1186\/s12885-018-4841-4","volume":"18","author":"S Hollunder","year":"2018","unstructured":"Hollunder S, Herrlinger U, Zipfel M, Schmolders J, Janzen V, Thiesler T, et al. Cross-sectional increase of adherence to multidisciplinary tumor board decisions. BMC Cancer. 2018, Sep, 29;18(1):936.","journal-title":"BMC Cancer"},{"issue":"5","key":"13540_CR41","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1245\/s10434-012-2676-9","volume":"20","author":"BW Lamb","year":"2013","unstructured":"Lamb BW, Taylor C, Lamb JN, Strickland SL, Vincent C, Green JSA, et al. Facilitators and barriers to teamworking and patient centeredness in multidisciplinary cancer teams: findings of a national study. Ann Surg Oncol. 2013, May, 1;20(5):1408\u201316.","journal-title":"Ann Surg Oncol"},{"key":"13540_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/JMDH.S117945","volume":"11","author":"T Soukup","year":"2018","unstructured":"Soukup T, Lamb BW, Arora S, Darzi A, Sevdalis N, Green JS. Successful strategies in implementing a multidisciplinary team working in the care of patients with cancer: an overview and synthesis of the available literature. J Multidiscip healthc. 2018, Dec, 31;11:49\u201361.","journal-title":"J Multidiscip healthc"},{"issue":"10","key":"13540_CR43","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/OP.20.00588","volume":"17","author":"T Soukup","year":"2021","unstructured":"Soukup T, Sevdalis N, Green JSA, Lamb BW, Chapman C, Skolarus TA. Making tumor boards more patient-centered: let\u2019s start with the name. JCO Oncol Pract. 2021, Oct;17(10):591\u201393.","journal-title":"JCO Oncol Pract"},{"key":"13540_CR44","unstructured":"Abendhardt W. Qualit\u00e4tssicherung: Tumorboards - Bessere Kooperation erforderlich. Deutsches \u00c4rzteblatt [Internet]. 2012, Aug, 6;109(31\u201332). Available from: https:\/\/www.aerzteblatt.de\/archiv\/128317\/Qualitaetssicherung-Tumorboards-Bessere-Kooperation-erforderlich. [cited 2023 Aug 20]."},{"key":"13540_CR45","unstructured":"Klein R, Nutzen HM. Mehraufwand und Finanzierung von Onkologischen Spitzenzentren, Onkologischen Zentren und Organkrebszentren [Internet]. Deutsche Krebshilfe, Deutsche Krebsgesellschaft; 2017 Jan. Available from: https:\/\/www.krebshilfe.de\/fileadmin\/Downloads\/PDFs\/Stellungnahmen\/Prognos_Endbericht_Deutsche_Krebshilfe.pdf. [cited 2023 Aug 20]."},{"issue":"2","key":"13540_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jso.21589","volume":"102","author":"NJL Hong","year":"2010","unstructured":"Hong NJL, Wright FC, Gagliardi AR, Paszat LF. Examining the potential relationship between multidisciplinary cancer care and patient survival: an international literature review. J Surg Oncol. 2010, Aug, 1;102(2):125\u201334.","journal-title":"J Surg Oncol"},{"issue":"6","key":"13540_CR47","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1177\/0272989X04271047","volume":"24","author":"F Kee","year":"2004","unstructured":"Kee F, Owen T, Leathem R. Decision making in a multidisciplinary cancer team: does team discussion result in better quality decisions? Med Decis Mak. 2004;24(6):602\u201313.","journal-title":"Med Decis Mak"},{"key":"13540_CR48","doi-asserted-by":"crossref","unstructured":"Kesson E, George A, Burns H, Morrison D. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women|the BMJ [Internet]. 2012. Available from: https:\/\/www.bmj.com\/content\/344\/bmj.e2718. [cited 2023 Aug 20].","DOI":"10.1136\/bmj.e2718"},{"key":"13540_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ctrv.2015.11.007","volume":"42","author":"B Pillay","year":"2016","unstructured":"Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev. 2016, Jan;42:56\u201372.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"13540_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12913-020-4930-3","volume":"20","author":"ML Specchia","year":"2020","unstructured":"Specchia ML, Frisicale EM, Carini E, Di Pilla A, Cappa D, Barbara A, et al. The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res. 2020, Jan, 31;20(1):73.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"13540_CR51","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/jnci\/djs502","volume":"105","author":"NL Keating","year":"2013","unstructured":"Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ. Tumor boards and the quality of cancer care. J Natl Cancer Inst. 2013, Jan, 16;105(2):113\u201321.","journal-title":"J Natl Cancer Inst"},{"key":"13540_CR52","doi-asserted-by":"crossref","unstructured":"Hermes-Moll K, Baumann W, Kowalski C, Ohlmeier C, Gothe H, Deutschland. Mvf HVMT. 2021, Oct;4(14(05\/2021)):57\u201361.","DOI":"10.24945\/MVF.05.21.1866-0533.2346"},{"issue":"2","key":"13540_CR53","first-page":"e12971","volume":"28","author":"J Bate","year":"2019","unstructured":"Bate J, Wingrove J, Donkin A, Taylor R, Whelan J. Patient perspectives on a national multidisciplinary team meeting for a rare cancer. Eur J Cancer Care (Engl). 2019, Mar;28(2):e12971.","journal-title":"Eur J Cancer Care (engl)"},{"issue":"10","key":"13540_CR54","first-page":"e0139921","volume":"10","author":"P Hahlweg","year":"2015","unstructured":"Hahlweg P, Hoffmann J, H\u00e4rter M, Frosch DL, Elwyn G, Scholl I. Absentia: an explor study of how patients are consid in multidiscip cancer team meetings. PLoS One. 2015, Oct, 6;10(10):e0139921.","journal-title":"Absentia: an Explor Study of How Patients are Consid in Multidiscip Cancer Team Meetings. PLoS One"},{"key":"13540_CR55","doi-asserted-by":"crossref","unstructured":"Heuser C, Diekmann A, Schellenberger B, Bohmeier B, Kuhn W, Karbach U, et al. Patient participation in multidisciplinary tumor conferences from the providers\u2019 perspective: is it feasible in routine cancer care? J Multidiscip Healthc. 2020 Nov 27: 1729\u201339, 13.","DOI":"10.2147\/JMDH.S283166"},{"issue":"11","key":"13540_CR56","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00761-020-00836-0","volume":"26","author":"G Kn\u00f6tgen","year":"2020","unstructured":"Kn\u00f6tgen G. Onkologische Pflege im Tumorboard. Onkologe (Berl). 2020;26(11):991\u201397.","journal-title":"Onkologe (Berl)"},{"issue":"11","key":"13540_CR57","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1470-2045(06)70940-8","volume":"7","author":"A Fleissig","year":"2006","unstructured":"Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? The Lancet Oncol. 2006, Nov;7(11):935\u201343.","journal-title":"The Lancet Oncol"},{"key":"13540_CR58","unstructured":"NHS. National cancer peer review programme report 2010\/2011 [Internet]. 2011 Nov. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/216205\/dh_131669.pdf. [cited 2023 Aug 18]."},{"key":"13540_CR59","doi-asserted-by":"publisher","first-page":"c951","DOI":"10.1136\/bmj.c951","volume":"340","author":"C Taylor","year":"2010","unstructured":"Taylor C, Munro AJ, Glynne-Jones R, Griffith C, Trevatt P, Richards M, et al. Multidisciplinary team working in cancer: what is the evidence? BMJ. 2010, Mar, 23;340:c951.","journal-title":"BMJ"},{"key":"13540_CR60","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-3-642-12840-0_6","volume-title":"Qualit\u00e4tsmanagement und Zertifizierung in der Onkologie [Internet]","author":"H Schmalenberg","year":"2010","unstructured":"Schmalenberg H. Interdisziplin\u00e4res Qualit\u00e4tsmanagement und Zentrumsbildung in der Onkologie. In: Schmalenberg H, Hartmann R, Baumann W, editors. Qualit\u00e4tsmanagement und Zertifizierung in der Onkologie [Internet]. Berlin, Heidelberg: Springer; 2010. p. 107\u201341. Available from: https:\/\/doi.org\/10.1007\/978-3-642-12840-0_6. [cited 2023 Jul 24]."},{"key":"13540_CR61","first-page":"70","volume":"174","author":"R Dengler","year":"2022","unstructured":"Dengler R, Straub N, Bredow L, Becker J, Hornschuch M, Riedel O, et al. Outpatient medical specialist care (ASV): a multiperspective study on status quo, challenges and perspectives. ZEFQ. 2022, Nov, 1;174:70\u201381.","journal-title":"ZEFQ"},{"key":"13540_CR62","unstructured":"IGES Institute. Wissenschaftliche Evaluation des Produktivbetriebs der Anwendungen der Telematikinfrastruktur 2022 [Internet]. 2023. Available from: https:\/\/www.gematik.de\/media\/gematik\/Medien\/Telematikinfrastruktur\/TI-Atlas\/IGES-Studie_Wissenschaftliche_Evaluation_des_Produktivbetriebs_der_Anwendungen_der_TI_2022.pdf. [cited 2023 Aug 21]."},{"issue":"7","key":"13540_CR63","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/1878-0261.12690","volume":"14","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Borras JM, Grau C. Provision and use of radiotherapy in Europe. Mol Oncol. 2020;14(7):1461\u201369.","journal-title":"Mol Oncol"},{"issue":"8","key":"13540_CR64","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40273-019-00801-9","volume":"37","author":"SJ Wright","year":"2019","unstructured":"Wright SJ, Newman WG, Payne K. Accounting for capacity constraints in economic evaluations of precision medicine: a systematic review. Pharmacoeconomics. 2019;37(8):1011\u201327.","journal-title":"Pharmacoeconomics"},{"key":"13540_CR65","unstructured":"ACS. Optimal resources for breast care 2024 standards [Internet]. 2023 Feb. Available from: https:\/\/accreditation.facs.org\/accreditationdocuments\/NAPBC\/Standards\/Optimal_Resources_for_Breast_Care_2024.pdf. [cited 2023 Aug 21]."},{"issue":"3","key":"13540_CR66","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10900-019-00776-w","volume":"45","author":"RW Dobbs","year":"2020","unstructured":"Dobbs RW, Stinson J, Vasavada SR, Caldwell BM, Freeman VL, Garvey DF, et al. Helping men find their way: improving prostate cancer clinic attendance via patient navigation. J Community Health. 2020, Jun, 1;45(3):561\u201368.","journal-title":"J Community Health"},{"issue":"6","key":"13540_CR67","doi-asserted-by":"publisher","first-page":"dju115","DOI":"10.1093\/jnci\/dju115","volume":"106","author":"KM Freund","year":"2014","unstructured":"Freund KM, Battaglia TA, Calhoun E, Darnell JS, Dudley DJ, Fiscella K, et al. Impact of patient navigation on timely cancer care: the patient navigation research program. J Natl Cancer Inst. 2014, Jun, 14;106(6):dju115.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"13540_CR68","first-page":"1","volume":"8","author":"B Albalooshi","year":"2020","unstructured":"Albalooshi B, M A, Bagheri F, Miyanath S, Ray B, Muhasin M, et al. Direct comparison of 99mTc-PSMA SPECT\/CT and 68Ga-PSMA PET\/CT in patients with prostate cancer. Asia Ocean J Nucl Med Biol. 2020;8(1):1\u20137.","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"3","key":"13540_CR69","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1148\/radiol.2021211351","volume":"301","author":"H Hricak","year":"2021","unstructured":"Hricak H, Ward ZJ, Atun R, Abdel-Wahab M, Muellner A, Scott AM. Increasing access to imaging for addressing the global cancer epidemic. Radiology. 2021, Sep, 28;301(3):543\u201346.","journal-title":"Radiology"},{"issue":"2","key":"13540_CR70","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2967\/jnumed.116.178939","volume":"58","author":"S Robu","year":"2017","unstructured":"Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I & amp;S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med. 2017, Feb;58(2):235\u201342.","journal-title":"J Nucl Med"},{"issue":"5","key":"13540_CR71","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1177\/1049732319889354","volume":"30","author":"N Bergen","year":"2020","unstructured":"Bergen N, Labont\u00e9 R. \u201cEverything Is Perfect, and We Have No Problems\u201d: detecting and limiting social desirability bias in qualitative research. Qual Health Res. 2020, Apr, 1;30(5):783\u201392.","journal-title":"Qual Health Res"},{"issue":"5","key":"13540_CR72","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1177\/1470785318805305","volume":"61","author":"RB Larson","year":"2019","unstructured":"Larson RB. Controlling social desirability bias. Int J Market Res. 2019, Sep, 1;61(5):534\u201347.","journal-title":"Int J Market Res"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-13540-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:51:22Z","timestamp":1781614282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-025-13540-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13540"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-13540-9","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"3 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Technical University of Munich waived the need for ethics approval for this interview study. All participants provided written informed consent prior to their participation in the study. In the case of employed physicians, additional written consent was obtained from their institution. The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This thesis was written as part of a master\u2019s thesis for the M.Sc. Health Science degree at the Technical University of Munich. The work was supervised by the Chair of Health Economics at the Technical University of Munich and Novartis Radiopharmaceuticals GmbH.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1281"}}